SCHEMBL23923900

SCHEMBL23923900

Cc1cc(S(C)(=O)=O)[nH]c1C(=O)O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 4/20 0.39
▸ KDM4E B2RXH2 3/20 0.39
▸ HPGD P15428 3/20 0.39
▸ HSD17B10 Q99714 2/20 0.39
▸ ALDH1A1 P00352 5/20 0.37
▸ MAPK1 P28482 2/20 0.37
▸ LMNA P02545 2/20 0.37
▸ NOTUM Q6P988 4/20 0.34
▸ MEN1 O00255 5/20 0.34
▸ KMT2A Q03164 5/20 0.34
▸ GFER P55789 3/20 0.34
▸ DAO P14920 1/20 0.33
▸ HCAR2 Q8TDS4 1/20 0.33
▸ GPR17 Q13304 1/20 0.33
▸ HTT P42858 2/20 0.32
▸ ATM Q13315 1/20 0.32
▸ RPA1 P27694 1/20 0.32
▸ MCL1 Q07820 1/20 0.32
▸ THRB P10828 1/20 0.32
▸ POLB P06746 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11057963 0.80 ALDH1A1 (0.39) GAAKDM4EHPGDHSD17B10ALDH1A1
SCHEMBL1044787 0.73 NOTUM (0.41) GAAKDM4EHPGDHSD17B10ALDH1A1
SCHEMBL4472003 0.71 ALOX15 (0.48) GAAKDM4EHPGDHSD17B10ALDH1A1
SCHEMBL6622235 0.69 NOTUM (0.39) GAAKDM4EHPGDHSD17B10ALDH1A1
SCHEMBL14157647 0.69 GPR35 (0.41) GAAKDM4EHPGDHSD17B10ALDH1A1
SCHEMBL6220712 0.67 GPR17 (0.50) KDM4EHPGDHSD17B10ALDH1A1GPR17
SCHEMBL4470824 0.67 HCAR2 (0.41) GAAKDM4EHPGDHSD17B10ALDH1A1
SCHEMBL17362887 0.65 KDM4E (0.43) GAAKDM4EHPGDHSD17B10POLB
SCHEMBL4575201 0.65 MAPK1 (0.35) MAPK1
SCHEMBL7820940 0.64 KDM4E (0.41) GAAKDM4EHPGDHSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122010912-A Antiviral 1, 3-dioxoindene compounds 诺华股份有限公司 2026-05-12 — — CN disclosed
US-20250188066-A1 ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2025-06-12 — — US disclosed
US-12286423-B2 Antiviral 1,3-di-oxo-indene compounds NOVARTIS AG (CH) 2025-04-29 — — US disclosed
CN-115867545-A Antiviral 1,3 dioxoindene compounds 诺华股份有限公司 2023-03-28 — — CN disclosed
EP-4139301-A1 ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS Novartis AG (CH) 2023-03-01 — — EP disclosed
WO-2021214080-A1 ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS NOVARTIS AG (CH) 2021-10-28 — — WO disclosed
WO-2021214080-A1 ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS NOVARTIS AG (CH) 2021-10-28 — — WO disclosed
US-20210323947-A1 ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS NOVARTIS AG (CH) 2021-10-21 — — US disclosed
US-20210323947-A1 ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS NOVARTIS AG (CH) 2021-10-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250188066-A1 ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS IRF3, EIF2AK2, ZC3HAV1 GAA 307/4885KDM4E 3114/4885HPGD 2579/4885
US-20210323947-A1 ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS IRF3, EIF2AK2, ZC3HAV1 GAA 307/4885KDM4E 3114/4885HPGD 2579/4885
US-12286423-B2 Antiviral 1,3-di-oxo-indene compounds IRF3, EIF2AK2, ZC3HAV1 GAA 307/4885KDM4E 3114/4885HPGD 2579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback